The Scientist

» immunotherapy

Most Recent

image: Contributors

Contributors

By | April 1, 2017

Meet some of the people featured in the April 2017 issue of The Scientist.

0 Comments

image: Gel Scaffolds for Delivery of Immunotherapies

Gel Scaffolds for Delivery of Immunotherapies

By | April 1, 2017

Using biocompatible polymers to carry cancer immune therapies directly to the tumor

0 Comments

image: Making CAR T-Cell Therapy Safer

Making CAR T-Cell Therapy Safer

By | April 1, 2017

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

0 Comments

Measuring PD-L1 levels was a great start. Now we need to quantify more protein biomarkers, assess the tumor mutational landscape, and examine immune cell signatures, too.

0 Comments

image: Neoantigens Enable Personalized Cancer Immunotherapy

Neoantigens Enable Personalized Cancer Immunotherapy

By | April 1, 2017

Tumors’ mutations can encode the seeds of their own destruction, in the form of immunogenic peptides recognized by T cells.

1 Comment

image: Infographic: Antibody Cancer Therapy

Infographic: Antibody Cancer Therapy

By | April 1, 2017

An experimental technique removes T cells that aid in vitro tumor growth.

0 Comments

image: Infographic: Targeting Cancer Antigens

Infographic: Targeting Cancer Antigens

By | April 1, 2017

Neoantigens may serve as valuable targets for new immunotherapies.

0 Comments

image: Targeting Tregs Halts Cancer’s Immune Helpers

Targeting Tregs Halts Cancer’s Immune Helpers

By | April 1, 2017

New monoclonal antibodies kill both cancer-promoting immunosuppressive cells and tumor cells in culture.

0 Comments

image: Tasmanian Devil Cancer Immunotherapy

Tasmanian Devil Cancer Immunotherapy

By | March 13, 2017

Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.

0 Comments

image: Kite’s CAR T-Cell Therapy Success

Kite’s CAR T-Cell Therapy Success

By | March 1, 2017

More than one-third of lymphoma patients in a Phase 2 trial were clear of disease at six months, and no new safety concerns arose since the company’s three-month follow up.

0 Comments

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. March for Science: Dispatches from Washington, DC
  4. Record-Setting Corn Grows 45 Feet Tall
AAAS